Clarity Pharmaceuticals Completes Patient Recruitment in Co-PSMA Imaging Trial

Clarity Pharmaceuticals Limited (ASX: CU6) has completed recruitment for its Co-PSMA Phase II imaging trial, evaluating its novel diagnostic agent ⁶⁴Cu-SAR-bisPSMA in prostate cancer patients experiencing biochemical recurrence. Led by Prof. Louise Emmett at St Vincent’s Hospital Sydney, the trial aims to compare the detection capabilities of Clarity’s agent with the current standard, ⁶⁸Ga-PSMA-11 PET/CT, in patients with low PSA levels post-prostatectomy. The study enrolled 50 participants and builds on promising data from Clarity’s earlier PROPELLER and COBRA trials. Advantages of ⁶⁴Cu-SAR-bisPSMA include better same-day imaging clarity, improved lesion detection due to higher contrast, and flexible scheduling enabled by copper-64’s longer half-life. The company is concurrently advancing Phase III CLARIFY and AMPLIFY trials. If successful, the new agent could enhance early cancer detection and treatment planning, addressing a key gap in current imaging solutions.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com